Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 5/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.37 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27031216 | 1.00 | DDB1 (0.39) | DDB1CRBNGPR119BACE1HCAR1 | |
| SCHEMBL27031107 | 0.97 | DDB1 (0.41) | DDB1CRBNGPR119BACE1 | |
| SCHEMBL29930514 | 0.97 | DDB1 (0.41) | DDB1CRBNGPR119BACE1 | |
| SCHEMBL29930570 | 0.94 | BACE1 (0.41) | DDB1CRBNBACE1CTSD | |
| SCHEMBL27031189 | 0.94 | BACE1 (0.41) | DDB1CRBNBACE1CTSD | |
| SCHEMBL29930874 | 0.92 | DDB1 (0.40) | DDB1CRBNGPR119BACE1CTSD | |
| SCHEMBL27031146 | 0.92 | DDB1 (0.40) | DDB1CRBNGPR119BACE1CTSD | |
| SCHEMBL29930847 | 0.90 | DDB1 (0.38) | DDB1CRBNGPR119 | |
| SCHEMBL27031088 | 0.90 | DDB1 (0.38) | DDB1CRBNGPR119 | |
| SCHEMBL29092604 | 0.88 | BCHE (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4308559-A1 | BENZISOXAZOLE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022195355-A1 | BENZISOXAZOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | HBZ, ZFX, WIZ | DDB1 1526/4885CRBN 820/4885GPR119 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.